Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Will Use siRNA Vectors to Help Dutch Partners Develop Tx for Spinal Disorders

NEW YORK, Sept. 14 (GenomeWeb News) - Galapagos will help Amsterdam Molecular Therapeutics, the Netherlands Institute for Brain Research, and the Vrije Universiteit Amsterdam develop treatments for acute spinal cord and peripheral nerve damage, the company said today.


The collaboration, funded in part by a2 million ($2.5 million) grant from the Dutch government organization Senter, aims to develop drugs that promote nerve regeneration and reduce the effect of neural scarring, Galapagos said.


Terms of the deal call for the Dutch company to provide access to its siRNA vectors on a fee-for-service basis. It is hoped that access to this technology will enable the partners to "discover protein targets involved in regeneration of injured nerve tissue."


Once these targets have been identified, Amsterdam Molecular Therapeutics will develop technologies based on their gene therapy platform. The Netherlands Institute for Brain Research, meantime, will use its expertise in neuroregeneration and microarray technology and the Vrije Universiteit Amsterdam will analyze nerve cell growth to further develop the therapeutics, according to Galapagos.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more